Diamedica Inc. announced the appointment of Dr. Todd Verdoorn as DiaMedica's Vice President of Neuroscience. Dr. Verdoorn has more than 26 years of experience working with both public and private companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb's stroke group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | -3.28% |
|
+36.57% | +3.87% |
06-27 | Transcript : DiaMedica Therapeutics Inc. - Special Call | |
06-26 | DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.87% | 112M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- Diamedica Inc. Appoints Todd Verdoorn as Vice President of Neuroscience